Wednesday, August 31, 2016 9:46:18 PM
• Patients with primary or recurrent Ta, G1-G2 NMIBC
• 562 evaluable patients per trial
• Central Pathology read as Ta, G1-G2
•Primary endpoint: Recurrence rate at 2 years
Individually, the trials did not reach statistical significance; SPI-611 p-value was 0.13 and SPI-612 p-value was 0.082. Even though it turns out there was a reason why the individual trials failed i.e. blood enzyme, DT-diaporase, in the bladder after resection, combining the 2 almost identical randomized placebo controlled multi-site studies, you get strong statistical significance (SS) with a p-value of 0.022. If one could do a reboot, one would just add several hundred pts to each trial in order to get SS from the get go. Another Q to answer
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM